Skip to main content

Xultophy® 100/3.6 (insulin degludec and liraglutide injection)

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. The response(s) are not intended to offer recommendations for administering Novo Nordisk products in a manner inconsistent with approved labeling. To access the Prescribing Information for Novo Nordisk products, please click here.

Search for Letters

Find documents for this product by entering your search terms in the box below.

 

Text: double click to edit.

Have a Question?

Request information directly from the Novo Nordisk
Medical Information department.